SCHEMBL343454

SCHEMBL343454

N#Cc1ccn2ccccc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IMPDH2 P12268 1/20 0.41
TSHR P16473 3/20 0.37
ALDH1A1 P00352 6/20 0.36
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
TDP1 Q9NUW8 1/20 0.36
ALOX15 P16050 1/20 0.36
KDM4E B2RXH2 3/20 0.35
LMNA P02545 2/20 0.35
MAPT P10636 3/20 0.35
GAA P10253 2/20 0.35
GLA P06280 1/20 0.35
HPGD P15428 1/20 0.35
EPHB3 P54753 1/20 0.35
HTT P42858 2/20 0.34
STAT3 P40763 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
NCOA3 Q9Y6Q9 1/20 0.34
DRD2 P14416 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28252963 0.86 IMPDH2 (0.39) IMPDH2TSHRALDH1A1MEN1KMT2A
SCHEMBL6005115 0.78 ALOX15 (0.36) ALOX15
SCHEMBL28646583 0.74 ALOX15 (0.36) ALDH1A1MEN1KMT2AALOX15KDM4E
SCHEMBL9098230 0.74 DRD2 (0.45) IMPDH2TSHRALDH1A1MEN1KMT2A
SCHEMBL10123651 0.72 CDC7 (0.33) IMPDH2ALDH1A1KDM4EGAAGLA
SCHEMBL10123575 0.71 MAOA (0.35) IMPDH2TSHRALDH1A1KMT2ASMN1; SMN2
SCHEMBL3670867 0.69 ALDH1A1 (0.37) TSHRALDH1A1MEN1KMT2AALOX15
SCHEMBL8829307 0.69 CYP19A1 (0.38) ALDH1A1MEN1KMT2ASMN1; SMN2GAA
SCHEMBL30736254 0.69 CYP19A1 (0.40) KMT2ALMNAMAPTGAAHTT
SCHEMBL10123585 0.69 ALDH1A1 (0.35) IMPDH2TSHRALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 108 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114276343-B Preparation method of fluorescent probe for detecting trace iron ions in chlorobenzene 中国石油化工股份有限公司 2023-07-07 CN claimed
CN-113582989-B Preparation method of cyanized or thiocyanized indolizine and derivatives thereof 广东药科大学 2022-07-08 CN claimed
CN-114276343-A Preparation method of fluorescent probe for detecting trace iron ions in chlorobenzene 中石化南京化工研究院有限公司 2022-04-05 CN claimed
CN-113582989-A Preparation method of cyanized or thiocyanized indolizine and derivatives thereof 广东药科大学 2021-11-02 CN claimed
CN-106661019-A Indolizine derivatives as phoshoinositide 3-kinases inhibitors 奇斯药制品公司 2017-05-10 CN claimed
US-9469741-B2 Polymers functionalized with heterocyclic nitrile compounds BRIDGESTONE CORPORATION (JP) 2016-10-18 US claimed
EP-2203482-B1 POLYMERS FUNCTIONALIZED WITH HETEROCYCLIC NITRILE COMPOUNDS BRIDGESTONE CORP (JP) 2015-11-25 EP claimed
CN-104945540-A Polymers functionalized with heterocyclic nitrile compounds BRIDGESTONE CORP 2015-09-30 CN claimed
US-20150267031-A1 POLYMERS FUNCTIONALIZED WITH HETEROCYCLIC NITRILE COMPOUNDS BRIDGESTONE CORPORATION (JP) 2015-09-24 US claimed
US-9085646-B2 Polymers functionalized with heterocyclic nitrile compounds BRIDGESTONE CORPORATION (JP) 2015-07-21 US claimed
US-20130066016-A1 POLYMERS FUNCTIONALIZED WITH HETEROCYCLIC NITRILE COMPOUNDS BRIDGESTONE CORPORATION (JP) 2013-03-14 US claimed
US-8362156-B2 Polymers functionalized with heterocyclic nitrile compounds BRIDGESTONE CORPORATION (JP) 2013-01-29 US claimed
US-8314189-B2 Polymers functionalized with heterocyclic nitrile compounds BRIDGESTONE CORPORATION (JP) 2012-11-20 US claimed
US-20100280217-A1 POLYMERS FUNCTIONALIZED WITH HETEROCYCLIC NITRILE COMPOUNDS BRIDGESTONE CORPORATION (JP) 2010-11-04 US claimed
CN-101874044-A Polymers functionalized with heterocyclic nitrile compounds BRIDGESTONE CORP 2010-10-27 CN claimed
EP-2203482-A1 POLYMERS FUNCTIONALIZED WITH HETEROCYCLIC NITRILE COMPOUNDS Bridgestone Corporation (JP) 2010-07-07 EP claimed
WO-2009051702-A1 POLYMERS FUNCTIONALIZED WITH HETEROCYCLIC NITRILE COMPOUNDS BRIDGESTONE CORPORATION (JP) 2009-04-23 WO claimed
WO-2009051700-A1 POLYMERS FUNCTIONALIZED WITH HETEROCYCLIC NITRILE COMPOUNDS BRIDGESTONE CORPORATION (US) 2009-04-23 WO claimed
US-20090099325-A1 POLYMERS FUNCTIONALIZED WITH HETEROCYCLIC NITRILE COMPOUNDS BRIDGESTONE CORPORATION 2009-04-16 US claimed
JP-3099079-A None JP disclosed
WO-2026102105-A1 FUNCTIONAL POLYBUTADIENE AND CARBON BLACK IN RUBBER COMPOUNDS BRIDGESTONE AMERICAS TIRE OPERATIONS, LLC (US) 2026-05-15 WO disclosed
CN-114276343-B Preparation method of fluorescent probe for detecting trace iron ions in chlorobenzene 中国石油化工股份有限公司 2023-07-07 CN disclosed
CN-114276343-B Preparation method of fluorescent probe for detecting trace iron ions in chlorobenzene 中国石油化工股份有限公司 2023-07-07 CN disclosed
US-11512148-B2 Composition including multiple terminally functionalized polymers BRIDGESTONE CORPORATION (JP) 2022-11-29 US disclosed
CN-113582989-B Preparation method of cyanized or thiocyanized indolizine and derivatives thereof 广东药科大学 2022-07-08 CN disclosed
US-20220153885-A1 PROCESS FOR PRODUCING FUNCTIONALIZED POLYMERS BRIDGESTONE CORPORATION (JP) 2022-05-19 US disclosed
CN-114276343-A Preparation method of fluorescent probe for detecting trace iron ions in chlorobenzene 中石化南京化工研究院有限公司 2022-04-05 CN disclosed
CN-113582989-A Preparation method of cyanized or thiocyanized indolizine and derivatives thereof 广东药科大学 2021-11-02 CN disclosed
CN-109415457-B Method for preparing functionalized polymers 株式会社普利司通 2021-05-25 CN disclosed
CN-111269228-B Preparation method of indolizine ring-1, 2-diketone and derivative thereof with fluorescence activity 广东药科大学 2021-04-23 CN disclosed
EP-3458488-B1 PROCESS FOR PRODUCING FUNCTIONALIZED POLYMERS BRIDGESTONE CORP (JP) 2020-12-30 EP disclosed
US-20200369791-A1 Composition Including Multiple Terminally Functionalized Polymers BRIDGESTONE CORPORATION (JP) 2020-11-26 US disclosed
US-20200190293-A1 RUBBER COMPOSITION, METHOD FOR MANUFACTURING RUBBER COMPOSITION, AND TIRE BRIDGESTONE CORPORATION (JP) 2020-06-18 US disclosed
CN-111269228-A Preparation method of indolizine ring-1, 2-diketone and derivative thereof with fluorescence activity 广东药科大学 2020-06-12 CN disclosed
EP-3608363-A1 RUBBER COMPOSITION, METHOD FOR PRODUCING RUBBER COMPOSITION, AND TIRE Bridgestone Corporation (JP) 2020-02-12 EP disclosed
US-10550203-B2 Polymers functionalized with heterocyclic nitrile compounds BRIDGESTONE CORPORATION (JP) 2020-02-04 US disclosed
CN-110494480-A Rubber composition, the manufacturing method of rubber composition and tire BRIDGESTONE CORP 2019-11-22 CN disclosed
US-10370460-B1 Process for producing functionalized polymers BRIDGESTONE CORPORATION (JP) 2019-08-06 US disclosed
US-20190185598-A1 Process For Producing Functionalized Polymers BRIDGESTONE CORPORATION (JP) 2019-06-20 US disclosed
EP-3458488-A1 PROCESS FOR PRODUCING FUNCTIONALIZED POLYMERS Bridgestone Corporation (JP) 2019-03-27 EP disclosed
CN-109415457-A The method for preparing functionalized polymeric 株式会社普利司通 2019-03-01 CN disclosed
US-20180319905-A1 POLYMERS FUNCTIONALIZED WITH HETEROCYCLIC NITRILE COMPOUNDS BRIDGESTONE CORPORATION (JP) 2018-11-08 US disclosed
US-9884928-B2 Polymers functionalized with activated nitrogen heterocycles containing a pendant functional group BRIDGESTONE CORPORATION (JP) 2018-02-06 US disclosed
WO-2017201397-A1 PROCESS FOR PRODUCING FUNCTIONALIZED POLYMERS BRIDGESTONE CORPORATION (JP) 2017-11-23 WO disclosed
US-9738738-B2 Polymers functionalized with activated nitrogen heterocycles containing a pendant functional group BRIDGESTONE CORPORATION (JP) 2017-08-22 US disclosed
EP-3029074-B1 POLYMERS FUNCTIONALIZED WITH HETEROCYCLIC NITRILE COMPOUNDS BRIDGESTONE CORP (JP) 2017-08-02 EP disclosed
CN-106661019-A Indolizine derivatives as phoshoinositide 3-kinases inhibitors 奇斯药制品公司 2017-05-10 CN disclosed
US-9643969-B2 (aza)indolizine derivative and pharmaceutical use thereof KISSEI PHARMACEUTICAL CO., LTD. (JP) 2017-05-09 US disclosed
US-20170015760-A1 POLYMERS FUNCTIONALIZED WITH HETEROCYCLIC NITRILE COMPOUNDS BRIDGESTONE CORPORATION (JP) 2017-01-19 US disclosed
US-9487476-B2 Catechol diethers as potent anti-HIV agents YALE UNIVERSITY (US) 2016-11-08 US disclosed
US-9469741-B2 Polymers functionalized with heterocyclic nitrile compounds BRIDGESTONE CORPORATION (JP) 2016-10-18 US disclosed
US-20160289355-A1 POLYMERS FUNCTIONALIZED WITH ACTIVATED NITROGEN HETEROCYCLES CONTAINING A PENDANT FUNCTIONAL GROUP BRIDGESTONE CORPORATION (JP) 2016-10-06 US disclosed
US-20160289354-A1 POLYMERS FUNCTIONALIZED WITH ACTIVATED NITROGEN HETEROCYCLES CONTAINING A PENDANT FUNCTIONAL GROUP BRIDGESTONE CORPORATION (JP) 2016-10-06 US disclosed
EP-3029074-A1 POLYMERS FUNCTIONALIZED WITH HETEROCYCLIC NITRILE COMPOUNDS Bridgestone Corporation (JP) 2016-06-08 EP disclosed
EP-2203482-B1 POLYMERS FUNCTIONALIZED WITH HETEROCYCLIC NITRILE COMPOUNDS BRIDGESTONE CORP (JP) 2015-11-25 EP disclosed
CN-104945540-A Polymers functionalized with heterocyclic nitrile compounds BRIDGESTONE CORP 2015-09-30 CN disclosed
US-20150267031-A1 POLYMERS FUNCTIONALIZED WITH HETEROCYCLIC NITRILE COMPOUNDS BRIDGESTONE CORPORATION (JP) 2015-09-24 US disclosed
US-9085646-B2 Polymers functionalized with heterocyclic nitrile compounds BRIDGESTONE CORPORATION (JP) 2015-07-21 US disclosed
CN-102365281-B Indolizine derivative and medical application thereof KISSEI PHARMACEUTICAL 2014-11-12 CN disclosed
US-20140288017-A1 CATECHOL DIETHERS AS POTENT ANTI-HIV AGENTS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2014-09-25 US disclosed
US-8748452-B2 Indolizine derivative and use thereof for medical purposes KISSEI PHARMACEUTICAL CO., LTD. (JP) 2014-06-10 US disclosed
US-8748452-B2 Indolizine derivative and use thereof for medical purposes KISSEI PHARMACEUTICAL CO., LTD. (JP) 2014-06-10 US disclosed
US-8748452-B2 Indolizine derivative and use thereof for medical purposes KISSEI PHARMACEUTICAL CO., LTD. (JP) 2014-06-10 US disclosed
US-20130217878-A1 (AZA)INDOLIZINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF KISSEI PHARMACEUTICAL CO., LTD. (JP) 2013-08-22 US disclosed
EP-2415771-B1 INDOLIZINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES KISSEI PHARMACEUTICAL (JP) 2013-07-31 EP disclosed
WO-2013056003-A2 CATECHOL DIETHERS AS POTENT ANTI-HIV AGENTS YALE UNIVERSITY (US) 2013-04-18 WO disclosed
US-20130066016-A1 POLYMERS FUNCTIONALIZED WITH HETEROCYCLIC NITRILE COMPOUNDS BRIDGESTONE CORPORATION (JP) 2013-03-14 US disclosed
US-8362156-B2 Polymers functionalized with heterocyclic nitrile compounds BRIDGESTONE CORPORATION (JP) 2013-01-29 US disclosed
US-8314189-B2 Polymers functionalized with heterocyclic nitrile compounds BRIDGESTONE CORPORATION (JP) 2012-11-20 US disclosed
US-8309657-B2 Rubber composition BRIDGESTONE CORPORATION (JP) 2012-11-13 US disclosed
EP-1990343-B1 Azaindoles AVENTIS PHARMA LTD (GB) 2012-04-04 EP disclosed
EP-2415771-A1 INDOLIZINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES Kissei Pharmaceutical Co., Ltd. (JP) 2012-02-08 EP disclosed
EP-2415771-A1 INDOLIZINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES Kissei Pharmaceutical Co., Ltd. (JP) 2012-02-08 EP disclosed
US-20120015972-A1 INDOLIZINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES KISSEI PHARMACEUTICAL CO., LTD. (JP) 2012-01-19 US disclosed
US-20120015972-A1 INDOLIZINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES KISSEI PHARMACEUTICAL CO., LTD. (JP) 2012-01-19 US disclosed
US-20120015972-A1 INDOLIZINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES KISSEI PHARMACEUTICAL CO., LTD. (JP) 2012-01-19 US disclosed
CN-102239211-A Rubber composition BRIDGESTONE CORP 2011-11-09 CN disclosed
US-20110196086-A1 RUBBER COMPOSITION BRIDGESTONE CORPORATION (JP) 2011-08-11 US disclosed
EP-2336233-A1 RUBBER COMPOSITION Bridgestone Corporation (JP) 2011-06-22 EP disclosed
US-7943616-B2 Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders AVENTIS PHARMACEUTICALS INC. (US) 2011-05-17 US disclosed
US-20100280217-A1 POLYMERS FUNCTIONALIZED WITH HETEROCYCLIC NITRILE COMPOUNDS BRIDGESTONE CORPORATION (JP) 2010-11-04 US disclosed
CN-101874044-A Polymers functionalized with heterocyclic nitrile compounds BRIDGESTONE CORP 2010-10-27 CN disclosed
EP-2233486-A1 Azaindoles Aventis Pharma Limited (GB) 2010-09-29 EP disclosed
EP-1263759-B1 AZAINDOLES AVENTIS PHARMA LTD (GB) 2010-09-08 EP disclosed
EP-2203482-A1 POLYMERS FUNCTIONALIZED WITH HETEROCYCLIC NITRILE COMPOUNDS Bridgestone Corporation (JP) 2010-07-07 EP disclosed
US-20100168125-A1 INDOLIZINES AND AZA-ANALOG DERIVATIVES THEREOF AS CNS ACTIVE COMPOUNDS DONSBACH, MARTIN (DE) 2010-07-01 US disclosed
CN-100509811-C Azaindoles AVENTIS PHARMA LTD (GB) 2009-07-08 CN disclosed
WO-2009051702-A1 POLYMERS FUNCTIONALIZED WITH HETEROCYCLIC NITRILE COMPOUNDS BRIDGESTONE CORPORATION (JP) 2009-04-23 WO disclosed
WO-2009051700-A1 POLYMERS FUNCTIONALIZED WITH HETEROCYCLIC NITRILE COMPOUNDS BRIDGESTONE CORPORATION (US) 2009-04-23 WO disclosed
US-20090099325-A1 POLYMERS FUNCTIONALIZED WITH HETEROCYCLIC NITRILE COMPOUNDS BRIDGESTONE CORPORATION 2009-04-16 US disclosed
EP-1990343-A2 Azaindoles Aventis Pharma Limited (GB) 2008-11-12 EP disclosed
CN-100379734-C Azaindoles AVENTIS PHARMA LTD (GB) 2008-04-09 CN disclosed
US-7227020-B2 Azaindoles AVENTIS PHARMA LIMITED (GB) 2007-06-05 US disclosed
US-20050267304-A1 Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders AVENTIS PHARMACEUTICALS INC. (US) 2005-12-01 US disclosed
CN-1665809-A Azaindoles AVENTIS PHARMA LTD (GB) 2005-09-07 CN disclosed
US-6897207-B2 Azaindoles AVENTIS PHARMACEUTICALS INC. (US) 2005-05-24 US disclosed
CN-1615873-A Azaindoles compound AVENTIS PHARMA LTD (GB) 2005-05-18 CN disclosed
US-20040198737-A1 Azaindoles AVENTIS PHARMA LIMITED (GB) 2004-10-07 US disclosed
US-6770643-B2 Azaindoles AVENTIS PHARMA LIMITED (GB) 2004-08-03 US disclosed
US-20040053931-A1 Azaindoles AVENTIS PHARMACEUTICALS INC. 2004-03-18 US disclosed
EP-1397360-A1 AZAINDOLES Aventis Pharma Limited (GB) 2004-03-17 EP disclosed
US-20040009983-A1 Azaindoles AVENTIS PHARMA LIMITED (GB) 2004-01-15 US disclosed
CN-1413213-A Azaindoles AVENTIS PHARMA LTD (GB) 2003-04-23 CN disclosed
WO-2003000688-A1 AZAINDOLES AVENTIS PHARMA LIMITED (GB) 2003-01-03 WO disclosed
EP-1263759-A2 AZAINDOLES Aventis Pharma Limited (GB) 2002-12-11 EP disclosed
WO-2001047922-A2 AZAINDOLES AVENTIS PHARMA LIMITED (GB) 2001-07-05 WO disclosed
CN-1059723-A Hete rocyclic derivatives FUJISAWA PHARMACEUTICAL CO (JP) 1992-03-25 CN disclosed
JP-H0399079-A INDOLIZINE DERIVATIVE KISSEI PHARMACEUT CO LTD 1991-04-24 JP disclosed
JP-H0399079-A INDOLIZINE DERIVATIVE KISSEI PHARMACEUT CO LTD 1991-04-24 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040198737-A1 Azaindoles CCNY, CCNO, CNKSR1 IMPDH2 4148/4885TSHR 608/4885ALDH1A1 4397/4885
US-20100168125-A1 INDOLIZINES AND AZA-ANALOG DERIVATIVES THEREOF AS CNS ACTIVE COMPOUNDS INMT, AANAT, AZI2 IMPDH2 106/4885TSHR 909/4885ALDH1A1 720/4885
US-20140288017-A1 CATECHOL DIETHERS AS POTENT ANTI-HIV AGENTS COMT, NNMT, PNMT IMPDH2 624/4885TSHR 4865/4885ALDH1A1 572/4885
US-20040053931-A1 Azaindoles CDKN1A, CDK7, CDK2 IMPDH2 394/4885TSHR 3097/4885ALDH1A1 939/4885
US-20130217878-A1 (AZA)INDOLIZINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF XDH, CHRM1, PON1 IMPDH2 31/4885TSHR 1426/4885ALDH1A1 331/4885
US-20120015972-A1 INDOLIZINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES XDH, INMT, PON1 IMPDH2 13/4885TSHR 1474/4885ALDH1A1 397/4885
US-20040009983-A1 Azaindoles CCNY, CCNO, CKS2 IMPDH2 4243/4885TSHR 252/4885ALDH1A1 4673/4885
US-20050267304-A1 Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders MAP3K20, MAP3K12, MAP3K19 IMPDH2 1472/4885TSHR 4578/4885ALDH1A1 3053/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.